NDATOPICALCREAM
Approved
Jan 1974
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
MONISTAT-DERM (miconazole nitrate) by Sight Sciences is clinical pharmacology miconazole nitrate exhibits fungicidal activity in vitro against species of the genus candida. Approved for vulvovaginal candidiasis, candidiasis, tinea cruris. First approved in 1974.
Drug data last refreshed 23h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MONISTAT-DERM is a topical miconazole nitrate cream indicated for vulvovaginal candidiasis, candidiasis, and tinea cruris. It exhibits fungicidal activity against Candida species through an unknown pharmacologic mechanism. The drug is administered topically with minimal systemic absorption.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), suggesting declining team expansion and focus shift toward managed care and legacy product optimization.
Mechanism of Action
CLINICAL PHARMACOLOGY Miconazole nitrate exhibits fungicidal activity in vitro against species of the genus Candida. The pharmacologic mode of action is unknown. Following intravaginal administration of miconazole nitrate, small amounts are absorbed. Administration of a single dose of miconazole…
Indications (3)
Worked on MONISTAT-DERM at Sight Sciences? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.